According to the information provided by The Fly, in a research note that was published on Thursday, securities analysts at Oppenheimer changed their recommendation for Fate Therapeutics (NASDAQ: FATE) from “outperform” to “market perform.”

As of late, commentary regarding the share price has been provided by several additional equity research analysts. In a research note that was published on November 16, Citigroup lowered their previous “buy” rating and price target of $87.00 that they had placed on shares of Fate Therapeutics to $800.00. The research note was about the company’s stock. Fate Therapeutics was given an “outperform” rating by SVB Leerink in a research report that was published on Tuesday, December 13, 2018. However, the analyst firm lowered its price objective on Fate Therapeutics shares from $64.00 to $62.00 during the same period. Goldman Sachs Group published a research note on Thursday, December 15, announcing that it would begin covering shares of Fate Therapeutics. The announcement was made in connection with the company’s previous trading session. They gave the company’s stock a rating of “sell” and suggested a “sell” price of $10.00 for the company’s stock. On October 10, which was a Monday, Canaccord Genuity Group released a research report in which it stated that it would begin providing coverage of shares of Fate Therapeutics. They gave the company a “buy” recommendation and set its stock price objective at $42.00.
Additionally, on Tuesday, December 13, Trust Financial decreased its price target on shares of Fate Therapeutics from $51.00 to $46.00 while maintaining its “buy” recommendation on the stock. Eleven analysts have suggested that investors buy the stock, four have suggested that investors keep their current holdings, and two have suggested that investors sell. According to the information from Bloomberg, the recommendation for Fate Therapeutics is a “Moderate Buy,” and the price target has been set at $58.31.
When trading began on Thursday, a share of Fate Therapeutics was $12.25 per share. The company’s market capitalization is currently valued at $1.19 billion, its price-to-earnings ratio stands at 4.02, and its beta stands at 1.56. Over the past year, the cost of a share of Fate Therapeutics has ranged from a high of $66.56 to a low of the same amount. The simple moving average of the company’s stock price over the past 50 days is $19.23, and the simple moving average over the past 200 days is $24.27.
In recent weeks, several hedge funds and other institutional investors have been very active in the market, purchasing and selling shares of the company under discussion. The Bank of New York Mellon Corporation’s ownership stake in Fate Therapeutics was raised by 11.3% during the company’s third fiscal quarter. Following acquiring an additional 39,739 shares in the biopharmaceutical company over the preceding three months, the Bank of New York Mellon Corporation now holds 390,269 shares in its portfolio. These shares are currently worth a total of $8,747,000 as of right now. Over the third quarter, Capital Impact Advisors LLC increased the proportion of Fate Therapeutics stock owned by an additional 22.7%. After purchasing an additional 3,747 shares of the biopharmaceutical company during the quarter, Capital Impact Advisors LLC is now the owner of the 20,273 shares in question. These shares are currently trading on the market for $408,000. Glenmede Trust Co. NA increased its position in Fate Therapeutics by purchasing additional shares during the third quarter, bringing its total investment to approximately $207,000. Through the third quarter, Alpha Paradigm Partners LLC increased the proportion of Fate Therapeutics stock owned by 28.3%. After making an additional purchase of 12,491 shares during the most recent period, Alpha Paradigm Partners LLC now owns a total of 56,644 shares of the biopharmaceutical company’s stock, which has a market value of $1,269,000. This brings Alpha Paradigm Partners LLC’s total number of shares owned by the company to 56,644 shares. During the third quarter, BNP Paribas Arbitrage SNC increased the amount of Fate Therapeutics stock owned by 150.3%, making this the final and most important point. BNP Paribas Arbitrage SNC increased its holdings in the biopharmaceutical company’s stock by purchasing an additional 160,430 shares during the most recent period. As a result of these purchases, the firm now owns a total of 267,178 shares of the company’s stock, which has a value of $5,987,000.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, is currently focusing on the development of programmed cellular immunotherapies for the treatment of cancer and other immunological diseases all over the world. These immunotherapies are intended to treat cancer as well as other immunological diseases. The company is currently working on several NK- and T-cell immuno-oncology programs, some of which are listed below: FT516 for the treatment of acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for the treatment of B-cell lymphoma and chronic lymphocytic leukemia; FT576 for the treatment of multiple myeloma; and FT819 for the treatment of

The post Oppenheimer downgraded Fate Therapeutics (NASDAQ:FATE) to “Market Perform.” appeared first on Best Stocks.